Please enable JS

DISCOVER

AI & DATA VISUALISATION

ARTIFICIAL INTELLIGENCE EMPOWERING
OUR SOLUTIONS AND DATA SERVICES

Our Data Science and software engineering teams continuously develop advanced features to create better user experience and improve productivity in our software solutions for clinical research (smart search engines, automated classification of trial documents, assisted coding etc,.).

Unstructured data becomes meaningful!

Thanks to our AI pipeline and our standards-based clinical database aggregating data from multiple sources (eCRFs, medical imaging, data, laboratory data etc …), we can propose advanced data processing based on machine learning and advanced statistics. We make your data a real lever to grow your business.

A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT

64 +

countries
involved

20 000 +

investigational
Centres

3 million +

patients
in database

50 000 +

users
worlwide

telemedicine technologies earth

LATEST NEWSOUR NEWS >

telemedecine technologies news

Telemedicine Technologies will be at Swiss Biotech Day 2025

April 29, 2025

May 5 & 6 – Basel Telemedicine Technologies is pleased to present its CleanWeb™ eClinical suite, offering flexible, regulatory-compliant solutions tailored to every phase of clinical trials. Our platform includes a wide range of modules, such as eCRF, Randomization & Trial Supply Management, ePRO, eTMF, eConsent, Data Visualization, Vigilance, Imaging, CTMS, and more. We invite […]

READ MORE
telemedecine technologies news

Drug development cost pharma $2.2B per asset in 2024 as GLP-1s drive financial return

April 29, 2025

Fierce Biotech The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as reported in Deloitte’s annual report, “Measuring the return from pharmaceutical innovation.” In 2024, the average […]

READ MORE
telemedecine technologies news

Adopting Flexible Strategies to Combat Capacity Shortages

April 29, 2025

Biopharm International In January 2025, Samsung Biologics signed a six-year, $1.4 billion contract manufacturing agreement with an as-yet undisclosed European pharmaceutical company, with production to take place at Samsung’s manufacturing site in Songdo, South Korea (1). Simultaneously, at the J.P. Morgan Healthcare Conference held in San Francisco, the company announced plans to complete construction of […]

READ MORE